Market News & Trends
Selkirk Pharma Appoints Colleen Dixon as New CEO
Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced…
Ipsen & Foreseen Biotechnology Announce Exclusive Global Licensing Agreement for Antibody-Drug Conjugate With First-In-Class Potential
Ipsen and Foreseen Biotechnology recently announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated…
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma Limited recently announced its plan to advance OK-101 into a Phase 2 clinical trial of neuropathic corneal pain which is expected to begin…
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational
Rentschler Biopharma SE recently announced the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA, is now…
Kane Biotech Signs Worldwide License Agreement With Omni Bioceutical Innovations
Kane Biotech Inc. recently announced it has signed a worldwide license agreement with Arizona-based Omni Bioceutical Innovations Inc. for its coactiv+ line of scalp care…
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Lisata Therapeutics, Inc. recently announced promising preclinical results for its investigational candidate, certepetide (formerly LSTA1). The data, presented in a poster by Dr. Dan G.…
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy
CARGO Therapeutics, Inc. recently announced The Lancet has published favorable data from a Phase 1, single-center clinical study (NCT04088890) by Stanford Medicine (Stanford), evaluating firi-cel,…
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
Oragenics, Inc. recently announced it has developed a new formulation for its novel neurosteroid. Oragenics’ lead drug candidate for concussion, ONP-002, is a new chemical…
EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio Antisense Strand
EnPlusOne Biosciences, Inc. recently announced it had achieved the successful synthesis of the antisense strand of the commercially approved siRNA drug, Leqvio (inclisiran), a treatment…
Intensity Therapeutics Announces First Patient Dosed in its Global Randomized, Phase 3 Study in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics, Inc. recently announced the first US patient has been dosed in its Phase 3 study to treat metastatic sarcoma (NCT06263231). The trial is…
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability & Safety Profile
IGC Pharma, Inc. recently announced preclinical data demonstrating TGR-63’s potential as an effective treatment for Alzheimer’s disease. Analysis of the partition coefficient and mass spectrometry…
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
Avalo Therapeutics, Inc. recently announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS)…
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma, Inc recently announced the completion of dosing for the last patient in the Phase 2/3 LIFT-AD clinical trial evaluating fosgonimeton in people with…
Prelude Therapeutics Announces Clinical Collaboration With Merck
Prelude Therapeutics Incorporated recently announced it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US…
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase 1/2 Trials for Huntington’s Disease Treatment
uniQure N.V. recently announced updated interim data including up to 24 months of follow-up data from 29 treated patients enrolled in the ongoing US and…
Obsidian Therapeutics Announces FDA Fast Track Designation for Advanced Melanoma Treatment
Obsidian Therapeutics, Inc. recently announced the US FDA has granted Fast Track Designation to OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte…
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics, Inc. recently announced the US FDA has indicated that it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee…
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations
Skinvisible Pharmaceuticals, Inc. recently announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose-controlling drugs), including a GLP-1 agonist and CB-1 receptor…
MedPharm & Tergus Pharma Merger Forms Topical & Transepithelial CDMO Leader
MedPharm, Ltd., an Ampersand Capital Partners portfolio company, and Tergus Pharma, a Great Point Partners portfolio company, recently announced a merger. The combined topical and…
Triclinic Labs, Inc. & ELDICO Scientific Announce Microcrystal Electron Diffraction Partnership
The two companies recently announced an exclusive strategic collaboration to introduce Microcrystal Electron Diffraction services and instruments to the North American market. Microcrystal Electron Diffraction…
